Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03234712 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 18
- Study locations
NCT03234712 is a Phase 1 study of Advanced Solid Tumors Cancer that has completed, run by AbbVie. The registered enrollment target is 62 participants, below the 347-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (82% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT03234712, a Phase 1 study of Advanced Solid Tumors Cancer, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.
Conditions Studied
Interventions
- DRUG ABBV-321
Study Locations (18)
Illinois
- Northwestern University Feinberg School of Medicine /ID# 165191 - Chicago
- University of Chicago /ID# 166064 - Chicago
- Northshore University Health System Dermatology Clinical Trials Unit /ID# 201095 - Skokie
California
- The Angeles Clinic and Researc /ID# 166133 - Los Angeles
- University of California, Davis Comprehensive Cancer Center /ID# 215012 - Sacramento
New York
- Columbia Univ Medical Center /ID# 167184 - New York
- Stony Brook University Hospital /ID# 216976 - Stony Brook
Victoria
- Monash Health /ID# 217435 - Clayton
- Austin Hospital /ID# 166137 - Heidelberg
Arkansas
- Highlands Oncology Group /ID# 166132 - Springdale
Kentucky
- University of Kentucky Markey Cancer Center /ID# 217665 - Lexington
Massachusetts
- Dana-Farber Cancer Institute /ID# 212920 - Boston
Missouri
- Washington University-School of Medicine /ID# 214955 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2021-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234712
The ClinicalTrials.gov registry entry for NCT03234712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (82% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABBV-321 is the first listed.
NCT03234712 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Illinois, California, New York.
Frequently Asked Questions
What is clinical trial NCT03234712 about?
NCT03234712 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)". This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpres...
What is the current status of trial NCT03234712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-10-10. Estimated completion is 2021-04-14.
What conditions does trial NCT03234712 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT03234712?
The interventions under investigation include: ABBV-321 (DRUG).
Who is sponsoring clinical trial NCT03234712?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03234712 being conducted?
This trial has 18 study locations across Arkansas, California, Illinois, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.